Consensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging : developments in HCC management
© 2023. The Author(s), under exclusive licence to European Society of Radiology..
The 10th Global Forum for Liver Magnetic Resonance Imaging (MRI) was held as a virtual 2-day meeting in October 2021, attended by delegates from North and South America, Asia, Australia, and Europe. Most delegates were radiologists with experience in liver MRI, with representation also from specialists in liver surgery, oncology, and hepatology. Presentations, discussions, and working groups at the Forum focused on the following themes: • Gadoxetic acid in clinical practice: Eastern and Western perspectives on current uses and challenges in hepatocellular carcinoma (HCC) screening/surveillance, diagnosis, and management • Economics and outcomes of HCC imaging • Radiomics, artificial intelligence (AI) and deep learning (DL) applications of MRI in HCC. These themes are the subject of the current manuscript. A second manuscript discusses multidisciplinary tumor board perspectives: how to approach early-, mid-, and late-stage HCC management from the perspectives of a liver surgeon, interventional radiologist, and oncologist (Taouli et al, 2023). Delegates voted on consensus statements that were developed by working groups on these meeting themes. A consensus was considered to be reached if at least 80% of the voting delegates agreed on the statements. CLINICAL RELEVANCE STATEMENT: This review highlights the clinical applications of gadoxetic acid-enhanced MRI for liver cancer screening and diagnosis, as well as its cost-effectiveness and the applications of radiomics and AI in patients with liver cancer. KEY POINTS: • Interpretation of gadoxetic acid-enhanced MRI differs slightly between Eastern and Western guidelines, reflecting different regional requirements for sensitivity vs specificity. • Emerging data are encouraging for the cost-effectiveness of gadoxetic acid-enhanced MRI in HCC screening and diagnosis, but more studies are required. • Radiomics and artificial intelligence are likely, in the future, to contribute to the detection, staging, assessment of treatment response and prediction of prognosis of HCC-reducing the burden on radiologists and other specialists and supporting timely and targeted treatment for patients.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
European radiology - 33(2023), 12 vom: 05. Dez., Seite 9152-9166 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Taouli, Bachir [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Contrast Media |
|---|
| Anmerkungen: |
Date Completed 27.11.2023 Date Revised 12.03.2024 published: Print-Electronic ErratumIn: Eur Radiol. 2023 Dec 19;:. - PMID 38112766 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00330-023-09928-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360009018 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360009018 | ||
| 003 | DE-627 | ||
| 005 | 20240312233134.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00330-023-09928-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1324.xml |
| 035 | |a (DE-627)NLM360009018 | ||
| 035 | |a (NLM)37500964 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Taouli, Bachir |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Consensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging |b developments in HCC management |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.11.2023 | ||
| 500 | |a Date Revised 12.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Eur Radiol. 2023 Dec 19;:. - PMID 38112766 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to European Society of Radiology. | ||
| 520 | |a The 10th Global Forum for Liver Magnetic Resonance Imaging (MRI) was held as a virtual 2-day meeting in October 2021, attended by delegates from North and South America, Asia, Australia, and Europe. Most delegates were radiologists with experience in liver MRI, with representation also from specialists in liver surgery, oncology, and hepatology. Presentations, discussions, and working groups at the Forum focused on the following themes: • Gadoxetic acid in clinical practice: Eastern and Western perspectives on current uses and challenges in hepatocellular carcinoma (HCC) screening/surveillance, diagnosis, and management • Economics and outcomes of HCC imaging • Radiomics, artificial intelligence (AI) and deep learning (DL) applications of MRI in HCC. These themes are the subject of the current manuscript. A second manuscript discusses multidisciplinary tumor board perspectives: how to approach early-, mid-, and late-stage HCC management from the perspectives of a liver surgeon, interventional radiologist, and oncologist (Taouli et al, 2023). Delegates voted on consensus statements that were developed by working groups on these meeting themes. A consensus was considered to be reached if at least 80% of the voting delegates agreed on the statements. CLINICAL RELEVANCE STATEMENT: This review highlights the clinical applications of gadoxetic acid-enhanced MRI for liver cancer screening and diagnosis, as well as its cost-effectiveness and the applications of radiomics and AI in patients with liver cancer. KEY POINTS: • Interpretation of gadoxetic acid-enhanced MRI differs slightly between Eastern and Western guidelines, reflecting different regional requirements for sensitivity vs specificity. • Emerging data are encouraging for the cost-effectiveness of gadoxetic acid-enhanced MRI in HCC screening and diagnosis, but more studies are required. • Radiomics and artificial intelligence are likely, in the future, to contribute to the detection, staging, assessment of treatment response and prediction of prognosis of HCC-reducing the burden on radiologists and other specialists and supporting timely and targeted treatment for patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Gadoxetic acid | |
| 650 | 4 | |a Hepatocellular carcinoma | |
| 650 | 4 | |a Magnetic resonance imaging | |
| 650 | 7 | |a gadolinium ethoxybenzyl DTPA |2 NLM | |
| 650 | 7 | |a Contrast Media |2 NLM | |
| 650 | 7 | |a Gadolinium DTPA |2 NLM | |
| 650 | 7 | |a K2I13DR72L |2 NLM | |
| 700 | 1 | |a Ba-Ssalamah, Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Chapiro, Julius |e verfasserin |4 aut | |
| 700 | 1 | |a Chhatwal, Jagpreet |e verfasserin |4 aut | |
| 700 | 1 | |a Fowler, Kathryn |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Tae Wook |e verfasserin |4 aut | |
| 700 | 1 | |a Knobloch, Gesine |e verfasserin |4 aut | |
| 700 | 1 | |a Koh, Dow-Mu |e verfasserin |4 aut | |
| 700 | 1 | |a Kudo, Masatoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jeong Min |e verfasserin |4 aut | |
| 700 | 1 | |a Murakami, Takamichi |e verfasserin |4 aut | |
| 700 | 1 | |a Pinato, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Ringe, Kristina I |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Tabrizian, Parissa |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Yoon, Jeong Hee |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Mengsu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Vilgrain, Valérie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European radiology |d 1991 |g 33(2023), 12 vom: 05. Dez., Seite 9152-9166 |w (DE-627)NLM087691310 |x 1432-1084 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2023 |g number:12 |g day:05 |g month:12 |g pages:9152-9166 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00330-023-09928-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2023 |e 12 |b 05 |c 12 |h 9152-9166 | ||